Three randomized, double-blind, multi-center trials studied the result of ACTOS 30 mg or 45 mg plus the sulfonylurea, metformin or insulin on HDL and LDL levels and subclass particle size profile in sufferers with type 2 diabetes over a 24-week period. More than 250 patients in the three research were randomized to one of the next treatment arms:.. Addition of insulin sensitizer provides lipid benefits for patients with type 2 diabetes Results of 3 studies show the oral anti-diabetic agent ACTOS , in conjunction with a sulfonylurea, insulin or metformin, led to triglyceride decreases and high-density lipoprotein cholesterol boosts that demonstrated statistically significant improvements from baseline.Olfson stated it took time to analyze the data, including weighting the leads to extrapolate national numbers. But the authors stated the results may possibly hold true today. The scholarly research was funded with grants from the National Institutes of Health, the American Base for Suicide Prevention and the New York Psychiatric Institute. Dr. Sharon Hirsch, a University of Chicago psychiatrist not really involved in the scholarly study, praised it for raising awareness about the issue and the high numbers of affected people who do not get help.